Education
About Us
Working with TipRanks
Follow Us
BONESUPPORT HOLDING AB (BOEUF)
OTHER OTC:BOEUF
BOEUF Stock Chart & Stats
$20.61
$0.00(0.00%)
At close: 4:00 PM EST
$20.61
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$18.39 - $35.82
Previous CloseN/A
Volume21.00
Average Volume (3M)123.00
Market Cap
$1.34B
Enterprise Value$11.54B
Total Cash (Recent Filing)$379.02M
Total Debt (Recent Filing)$11.27M
Price to Earnings (P/E)88.2
Beta0.08
Next Earnings
Feb 24, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding65,859,190
10 Day Avg. Volume111
30 Day Avg. Volume123
Financial Highlights & Ratios
PEG Ratio-4.14
Price to Book (P/B)34.90
Price to Sales (P/S)28.25
P/FCF Ratio423.67
Enterprise Value/Market Cap8.64
Enterprise Value/Revenue10.31
Enterprise Value/Gross Profit11.13
Enterprise Value/Ebitda52.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross Margin And Solid Net MarginA 92.6% gross margin indicates strong product pricing power and differentiated technology in bone regeneration. Sustained high gross margins support durable profitability, fund R&D and commercial expansion, and provide a buffer against reimbursement pressure over the next 2–6 months.
Very Low Leverage And Strong Equity BaseMinimal financial leverage and a high equity ratio give BONEX flexibility to invest in clinical programs, geographic expansion, or absorb temporary reimbursement shocks. Strong ROE shows efficient capital use, underpinning balance-sheet resilience in coming quarters.
U.S. CERAMENT G Traction And Robust Cash GenerationRapid U.S. uptake of CERAMENT G and healthy operating cash flow create a durable revenue and cash base. A strong cash position and high-growth guidance enable continued commercial investment and shorten payback on new account penetration over the medium term.
Bears Say
Emerging U.S. Tariff Cost RiskTariffs represent a structural increase in cost of goods sold for U.S. operations that will phase in through 2027. Unless offset by pricing or productivity gains, this can compress margins and force tougher commercial decisions, affecting medium-term profitability and investment plans.
Persistent Weakness In Germany And UK MarketsOngoing contractions in Germany and slow UK recoveries reduce geographic diversification and demand predictability. Structural health-system backlogs and reimbursement timing can delay adoption of advanced biomaterials, reducing revenue resiliency across 2–6 months.
Product Mix And Margin Pressure From BVF Decline And Softer MarginsA decline in CERAMENT BVF volumes and slight EBIT/EBITDA margin erosion signal product-mix and operational pressures. If persistent, these trends could limit margin expansion from core products and require further commercial or cost actions to sustain profitability.
BONESUPPORT HOLDING AB News
BOEUF FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was $18.39 and its highest was $35.82 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is $1.34B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Feb 24, 2026 which is in 8 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Oct 23, 2025. The company reported $0.058 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.032.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.1.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of $0.058 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went down -9.74%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in BOEUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
BOEUF Company Deck
BOEUF Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales growth and successful product performance, particularly for CERAMENT G in the U.S., along with robust cash flow and strategic advancements such as the CeraHip study publication. However, these positive outcomes were tempered by significant currency impacts, challenges in key markets like Germany and the UK, technical disruptions during the call, and certain product sales declines.View all BOEUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
10.85% Mutual Funds
― Other Institutional Investors
83.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---